- Home
- SEED vs ICCM Comparison
SEED vs ICCM Comparison
Compare SEED & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEED
- ICCM
- Stock Information
- Founded
- SEED 1997
- ICCM 2006
- Country
- SEED China
- ICCM Israel
- Employees
- SEED N/A
- ICCM N/A
- Industry
- SEED Farming/Seeds/Milling
- ICCM
- Sector
- SEED Consumer Staples
- ICCM
- Exchange
- SEED Nasdaq
- ICCM Nasdaq
- Market Cap
- SEED 18.3M
- ICCM 29.3M
- IPO Year
- SEED N/A
- ICCM N/A
- Fundamental
- Price
- SEED $3.06
- ICCM $0.57
- Analyst Decision
- SEED
- ICCM Strong Buy
- Analyst Count
- SEED 0
- ICCM 2
- Target Price
- SEED N/A
- ICCM $2.70
- AVG Volume (30 Days)
- SEED 30.1K
- ICCM 409.5K
- Earning Date
- SEED 11-01-2024
- ICCM 11-13-2024
- Dividend Yield
- SEED N/A
- ICCM N/A
- EPS Growth
- SEED N/A
- ICCM N/A
- EPS
- SEED 1.21
- ICCM N/A
- Revenue
- SEED $16,516,031.00
- ICCM $3,336,000.00
- Revenue This Year
- SEED N/A
- ICCM $18.61
- Revenue Next Year
- SEED N/A
- ICCM $54.91
- P/E Ratio
- SEED $2.37
- ICCM N/A
- Revenue Growth
- SEED 64.93
- ICCM 3.60
- 52 Week Low
- SEED $1.37
- ICCM $0.48
- 52 Week High
- SEED $6.38
- ICCM $1.57
- Technical
- Relative Strength Index (RSI)
- SEED 49.63
- ICCM 45.18
- Support Level
- SEED $2.82
- ICCM $0.51
- Resistance Level
- SEED $3.11
- ICCM $0.61
- Average True Range (ATR)
- SEED 0.20
- ICCM 0.04
- MACD
- SEED -0.03
- ICCM -0.00
- Stochastic Oscillator
- SEED 29.36
- ICCM 64.19
About SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company. In crop seed biotechnologies, the company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.